Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

By Q. Anstee, G. Targher, C. Day. Nature Reviews Gastroenterology &Hepatology, 2013

1,661 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/ac31e1158afea42cb38b7ca40c6cb495068c4ff0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Pathology and Forensic Medicine

Citations in the corpus

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. (2016, background): “, NASH with varying amounts of fibrosis), exacerbates hepatic/peripheral insulin resistance, predisposes to atherogenic dyslipidemia and releases a variety of proinflammatory, vasoactive and thrombogenic factors that may promote the development of CVD [3–6,10].”
Morbidity and mortality associated with obesity. (2017, background): “NAFLD is the most common cause of chronic liver disease in the United States (55,56).”
Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss (2022, background): “Risk factors People with NAFLD generally have characteristics of MS, with the associated cardiovascular disease risk factors [15, 16].”
Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. (2015, background): “Moreover, while most studies cknowledge NAFLD to be a risk factor for T2D [24], the notion that AFLD anticipates the future development of components of the etabolic syndrome other than T2D is far less accepted, although t has been suggested by few authors [23,25,26] mainly based on heir expert opin”
Hepatic fibrosis: Concept to treatment. (2015, background): “more prevalent risk factors for progression [78] and must be distributed equally among study groups in a clinical trial.”
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? (2018, background): “Substantial evidence also indicates that people with T2DM are at high risk of developing NASH, and a twofold to fourfold higher risk of developing serious liver-related complications (cirrhosis, liver failure and HCC).(1,4,59,60) Notably, in dual biopsy studies the development of incident T2DM was t”
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 (2015, background): “First, as reported previously, patients with NAFLD do not seem to get screening for HCC as compared to those with HCV.12 Additionally, ultrasound (the current HCC screening tool) may fail to pick up small tumors in NAFLD patients owing to visceral obesity and intrahepatic fat.13,14 Third, there are ”
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases (2017, background): “3 However, this liver-centric view does not encompass the wider rami ﬁ cations of NAFLD.”